British national newspaper The Times reported on Thursday that senior sources in the British government expect that a verdict on whether US pharmaceutical company Pfizer Inc's (NYSE:PFE) COVID-19 vaccine works, will be available before the results are in on British pharmaceutical company AstraZeneca Plc's (STO:AZN)(LON:AZN) competing vaccine.
The Times report said that Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE, could be ready to distribute before Christmas.
Reportedly, Pfizer's Chief Executive, Albert Bourla, had previously said the company could release data on whether or not the vaccine works as early as October 2020.
Pfizer had said this week if trials are successful the company expects to file for emergency authorisation of the vaccine candidate from US regulators shortly after it has enough safety data in late November 2020.
According to Reuters news agency, Britain has supply deals for six vaccine candidates, including frontrunners from Pfizer and AstraZeneca.
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
LakeShore Biopharma receives Nasdaq delisting determination letter
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
GC Biopharma files IND for Phase 3 trial of BARYCELA in Thailand
Novavax COVID-19 vaccine approved in US
WHO and UNICEF deploy PharmaJet's Tropis ID system in Afghanistan polio campaign
FDA grants priority review for GSK's gepotidacin gonorrhoea indication